Mauritius

Mauritius

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.87 (2.39 - 3.27) 2019 Modelled IHME
2.82 (2.38 - 3.17) 2018 Modelled IHME
2.82 (2.38 - 3.19) 2017 Modelled IHME
2.91 (2.45 - 3.32) 2016 Modelled IHME
3.05 (2.50 - 3.55) 2015 Modelled IHME
3.11 (2.58 - 3.59) 2014 Modelled IHME
3.16 (2.65 - 3.62) 2013 Modelled IHME
3.2 (2.71 - 3.66) 2012 Modelled IHME
3.24 (2.75 - 3.69) 2011 Modelled IHME
3.28 (2.77 - 3.76) 2010 Modelled IHME
3.32 (2.79 - 3.79) 2009 Modelled IHME
3.36 (2.84 - 3.83) 2008 Modelled IHME
3.39 (2.87 - 3.86) 2007 Modelled IHME
3.43 (2.86 - 3.95) 2006 Modelled IHME
3.48 (2.82 - 4.03) 2005 Modelled IHME
3.53 (2.91 - 4.06) 2004 Modelled IHME
3.59 (3 - 4.09) 2003 Modelled IHME
3.65 (3.08 - 4.15) 2002 Modelled IHME
3.71 (3.12 - 4.23) 2001 Modelled IHME
3.77 (3.14 - 4.35) 2000 Modelled IHME
3.83 (3.19 - 4.39) 1999 Modelled IHME
3.9 (3.21 - 4.46) 1998 Modelled IHME
3.97 (3.22 - 4.54) 1997 Modelled IHME
4.02 (3.23 - 4.63) 1996 Modelled IHME
4.05 (3.24 - 4.72) 1995 Modelled IHME
4.05 (3.29 - 4.69) 1994 Modelled IHME
4.05 (3.33 - 4.67) 1993 Modelled IHME
4.05 (3.35 - 4.68) 1992 Modelled IHME
4.04 (3.37 - 4.70) 1991 Modelled IHME
4.03 (3.38 - 4.74) 1990 Modelled IHME
1.86 (0.21 - 18.22) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.42 (0.30 - 0.56) 2019 Modelled IHME
0.5 (0.36 - 0.65) 2018 Modelled IHME
0.53 (0.38 - 0.70) 2017 Modelled IHME
0.51 (0.37 - 0.66) 2016 Modelled IHME
0.47 (0.34 - 0.65) 2015 Modelled IHME
0.44 (0.31 - 0.61) 2014 Modelled IHME
0.41 (0.29 - 0.55) 2013 Modelled IHME
0.37 (0.27 - 0.49) 2012 Modelled IHME
0.35 (0.25 - 0.46) 2011 Modelled IHME
0.34 (0.24 - 0.45) 2010 Modelled IHME
0.34 (0.24 - 0.44) 2009 Modelled IHME
0.33 (0.24 - 0.44) 2008 Modelled IHME
0.33 (0.24 - 0.44) 2007 Modelled IHME
0.33 (0.24 - 0.44) 2006 Modelled IHME
0.33 (0.24 - 0.44) 2005 Modelled IHME
0.33 (0.24 - 0.44) 2004 Modelled IHME
0.34 (0.24 - 0.44) 2003 Modelled IHME
0.34 (0.25 - 0.46) 2002 Modelled IHME
0.35 (0.26 - 0.47) 2001 Modelled IHME
0.36 (0.26 - 0.49) 2000 Modelled IHME
0.58 (0.42 - 0.78) 1999 Modelled IHME
1.08 (0.76 - 1.44) 1998 Modelled IHME
1.68 (1.18 - 2.23) 1997 Modelled IHME
2.18 (1.51 - 2.87) 1996 Modelled IHME
2.39 (1.66 - 3.14) 1995 Modelled IHME
2.39 (1.69 - 3.15) 1994 Modelled IHME
2.39 (1.72 - 3.15) 1993 Modelled IHME
2.38 (1.73 - 3.12) 1992 Modelled IHME
2.36 (1.73 - 3.10) 1991 Modelled IHME
2.33 (1.73 - 3.08) 1990 Modelled IHME
0.61 (0.07 - 7.19) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
33 (24 - 43) 2019 Modelled IHME
33 (25 - 44) 2018 Modelled IHME
34 (25 - 44) 2017 Modelled IHME
34 (26 - 44) 2016 Modelled IHME
35 (26 - 45) 2015 Modelled IHME
34 (26 - 44) 2014 Modelled IHME
34 (26 - 44) 2013 Modelled IHME
35 (26 - 44) 2012 Modelled IHME
35 (27 - 45) 2011 Modelled IHME
35 (27 - 45) 2010 Modelled IHME
35 (27 - 45) 2009 Modelled IHME
36 (28 - 46) 2008 Modelled IHME
37 (28 - 47) 2007 Modelled IHME
37 (29 - 47) 2006 Modelled IHME
37 (29 - 47) 2005 Modelled IHME
37 (29 - 47) 2004 Modelled IHME
37 (29 - 47) 2003 Modelled IHME
37 (29 - 47) 2002 Modelled IHME
37 (29 - 47) 2001 Modelled IHME
37 (29 - 47) 2000 Modelled IHME
37 (29 - 47) 1999 Modelled IHME
37 (29 - 48) 1998 Modelled IHME
38 (29 - 48) 1997 Modelled IHME
38 (29 - 48) 1996 Modelled IHME
38 (29 - 49) 1995 Modelled IHME
38 (29 - 49) 1994 Modelled IHME
39 (30 - 49) 1993 Modelled IHME
39 (30 - 49) 1992 Modelled IHME
39 (30 - 49) 1991 Modelled IHME
40 (31 - 50) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
97 2018 Survey/reported WHO/UNICEF
96 2017 Survey/reported WHO/UNICEF
72 2016 Survey/reported WHO/UNICEF
97 2015 Survey/reported WHO/UNICEF
97 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
98 2012 Survey/reported WHO/UNICEF
98 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
99 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
97 2007 Survey/reported WHO/UNICEF
97 2006 Survey/reported WHO/UNICEF
97 2005 Survey/reported WHO/UNICEF
98 2004 Survey/reported WHO/UNICEF
97 2003 Survey/reported WHO/UNICEF
88 2002 Survey/reported WHO/UNICEF
92 2001 Survey/reported WHO/UNICEF
88 2000 Survey/reported WHO/UNICEF
85 1999 Survey/reported WHO/UNICEF
90 1998 Survey/reported WHO/UNICEF
90 1997 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
118 (60 - 235) 2015 Survey/reported Mauritius National AIDS Secretariat, 2015
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.31 (1.06 - 1.58) 2019 Modelled IHME
1.3 (1.06 - 1.59) 2018 Modelled IHME
1.3 (1.04 - 1.60) 2017 Modelled IHME
1.3 (1.07 - 1.59) 2016 Modelled IHME
1.31 (1.08 - 1.59) 2015 Modelled IHME
1.31 (1.08 - 1.60) 2014 Modelled IHME
1.31 (1.08 - 1.62) 2013 Modelled IHME
1.32 (1.09 - 1.63) 2012 Modelled IHME
1.33 (1.08 - 1.63) 2011 Modelled IHME
1.33 (1.09 - 1.65) 2010 Modelled IHME
1.34 (1.09 - 1.65) 2009 Modelled IHME
1.36 (1.10 - 1.66) 2008 Modelled IHME
1.37 (1.11 - 1.67) 2007 Modelled IHME
1.39 (1.12 - 1.68) 2006 Modelled IHME
1.4 (1.13 - 1.70) 2005 Modelled IHME
1.42 (1.15 - 1.71) 2004 Modelled IHME
1.44 (1.16 - 1.74) 2003 Modelled IHME
1.45 (1.18 - 1.77) 2002 Modelled IHME
1.47 (1.19 - 1.81) 2001 Modelled IHME
1.48 (1.19 - 1.84) 2000 Modelled IHME
1.48 (1.20 - 1.82) 1999 Modelled IHME
1.49 (1.21 - 1.83) 1998 Modelled IHME
1.49 (1.21 - 1.82) 1997 Modelled IHME
1.49 (1.21 - 1.83) 1996 Modelled IHME
1.49 (1.21 - 1.82) 1995 Modelled IHME
1.5 (1.21 - 1.83) 1994 Modelled IHME
1.5 (1.22 - 1.83) 1993 Modelled IHME
1.51 (1.22 - 1.84) 1992 Modelled IHME
1.51 (1.21 - 1.85) 1991 Modelled IHME
1.52 (1.20 - 1.86) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

People who inject drugs (PWID)
Download
Value (%) Year Type Source
97.3 (95.40 - 98.40) 2019 Modelled Granados-Garcia V et al, 2019
97.1 (96 - 98.10) 2011 Modelled Degenhardt L et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
28 (20 - 37) 2019 Modelled IHME
28 (20 - 37) 2018 Modelled IHME
28 (20 - 37) 2017 Modelled IHME
28 (20 - 36) 2016 Modelled IHME
27 (19 - 36) 2015 Modelled IHME
27 (19 - 36) 2014 Modelled IHME
28 (19 - 36) 2013 Modelled IHME
28 (20 - 36) 2012 Modelled IHME
27 (19 - 35) 2011 Modelled IHME
27 (20 - 35) 2010 Modelled IHME
27 (19 - 35) 2009 Modelled IHME
27 (19 - 35) 2008 Modelled IHME
27 (19 - 35) 2007 Modelled IHME
27 (19 - 35) 2006 Modelled IHME
27 (19 - 35) 2005 Modelled IHME
27 (19 - 35) 2004 Modelled IHME
27 (19 - 35) 2003 Modelled IHME
27 (19 - 35) 2002 Modelled IHME
27 (19 - 35) 2001 Modelled IHME
27 (19 - 35) 2000 Modelled IHME
27 (19 - 35) 1999 Modelled IHME
27 (19 - 35) 1998 Modelled IHME
27 (19 - 35) 1997 Modelled IHME
27 (19 - 35) 1996 Modelled IHME
27 (19 - 35) 1995 Modelled IHME
27 (19 - 35) 1994 Modelled IHME
26 (19 - 35) 1993 Modelled IHME
27 (19 - 35) 1992 Modelled IHME
26 (19 - 34) 1991 Modelled IHME
26 (18 - 34) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (60 - 235) 2015 Survey/reported Mauritius National AIDS Secretariat, 2015
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.87 (%)
2019
(2.39 - 3.27(%))
IHME
HCV (RNA/cAg+)
1.31 (%)
2019
(1.06 - 1.58(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
76
2019
(56 - 103)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
88
2019
(64 - 117)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.42 (%)
2019, latest modelled
(0.30 - 0.56(%))
IHME

Prevalence PWID

HCV
97.30 (%)
2019, latest modelled
(95.40 - 98.40(%))
Granados-Garcia V et al, 2019

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
118
2015
(60 - 235)
Mauritius National AIDS Secretariat, 2015
Eligible for HBV generic medicines
Eligible for HCV generic medicines